Daniel Aaron Pollyea

This study identifies NAMPT as a metabolic vulnerability in HR-MDS HSPCs, showing its inhibition reduces their survival and disease burden.

This study characterizes myeloid sarcoma through multi-omic profiling, identifies RAS pathway activation as a hallmark, and shows RAS inhibition reduces tumor burden in mouse models.